Synopsis Patients with type 1 diabetes mellitus (T1DM) for a duration of over five years do still produce C-peptide at a detectable level that further increases with the intake of a meal. This indicates that the pancreatic beta cells in T1DM patients are still able to respond to carbohydrate. This study explores the possibility of achieving reduced insulin requirements by adding glucagon-like peptide-1 ( GLP-1) receptor agonists (GLP-1RA) such as Liraglutide and Duraglutide to the insulin treatment regimen in C-peptide positive T1DM patients.
This week’s “ MED FACT ” discusses a retrospective study from Diabetes, Obesity, and Metabolism , ‘ Addition of GLP‐1RA therapy to Insulin in C‐peptide Positive Patients With Type 1 Diabetes ’, Dec 2018. Authors : Nitesh D Kuhadiya, Ben Prohaska, Husam Ghanim et al . Key Takeaways: Addition of GLP-1RA to insulin therapy in T1DM patients was…
